Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02141399 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Safety Study of ALKS 5461
A Phase 3 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,485
- Enrollment target
NCT02141399: Completed Phase 3 study, sponsored by Alkermes.
NCT02141399 is a Phase 3 study that has completed, run by Alkermes. The registered enrollment target is 1,485 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02141399, a Phase 3 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,485 participants
- Enrollment target
Study Summary
This is a 52-week open-label study to evaluate the safety and tolerability of ALKS 5461.
Interventions
- DRUG ALKS 5461
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,485 participants |
| Start Date | 2014-05 |
| Est. Completion | 2017-11-20 |
| Phase | Phase 3 |
What the finished NCT02141399 record still lists
NCT02141399 is an interventional study that assigns participants to a tested intervention. Its 1,485 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% higher).
The record links to 0 conditions, and to 1 intervention - of which ALKS 5461 is the first listed.
NCT02141399 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02141399 about?
NCT02141399 is a clinical study titled "A Long-Term Safety Study of ALKS 5461". This is a 52-week open-label study to evaluate the safety and tolerability of ALKS 5461.
What is the current status of trial NCT02141399?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,485 participants. The study started on 2014-05. Estimated completion is 2017-11-20.
What interventions are being tested in trial NCT02141399?
The interventions under investigation include: ALKS 5461 (DRUG).
Who is sponsoring clinical trial NCT02141399?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02141399's enrollment target sits among peer trials
1,485 163rd of 2000 higher than 1,838 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05869552 · 1,485 participants · NA
Preventing Suicide Among Sexual and Gender Diverse Young Adults in Primary Care
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia